Cargando…

Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO–positive acute myeloid leukemia

Objective: We aimed to explore a new method to reverse early relapse in patients with AML1-ETO–positive acute myeloid cell transplantation. Methods: A chidamide-based 3-drug combination regimen was used in our center to treat patients with AML1-ETO–positive AML post transplantation but negative flow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xi, Yang, Chenglong, Li, Rong, Zhang, Wen, Wang, Yu, Wang, Jiao, Chen, Juan, Huang, Feifei, Che, Rong, Xiao, Tao, Jiang, Hui, Li, Xiaobing, Huang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880285/ https://www.ncbi.nlm.nih.gov/pubmed/36712661 http://dx.doi.org/10.3389/fphar.2022.1059930

Ejemplares similares

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
por: Meng, Guangqiang, et al.
Publicado: (2019)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway
por: Liu, Jing, et al.
Publicado: (2020)

Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia
por: Chen, Xiaoyan, et al.
Publicado: (2021)

Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia
por: Yu, Guopan, et al.
Publicado: (2018)

Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients
por: Xi, Yang, et al.
Publicado: (2021)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients
por: Yang, Min, et al.
Publicado: (2022)

FACSorting help to analyze a rare case of acute myeloid leukemia with concurrent AML1‐ETO and PML‐RARA
por: Chen, Man, et al.
Publicado: (2021)

Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia
por: Mi, Ruihua, et al.
Publicado: (2021)

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
por: Barbetti, V, et al.
Publicado: (2013)

KDM4B promotes acute myeloid leukemia associated with AML1‐ETO by regulating chromatin accessibility
por: Ueda, Takeshi, et al.
Publicado: (2021)

Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report
por: He, Zhipeng, et al.
Publicado: (2019)

AML1-ETO-Related Fusion Circular RNAs Contribute to the Proliferation of Leukemia Cells
por: Wang, Ying, et al.
Publicado: (2022)

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
por: Dou, Liping, et al.
Publicado: (2019)

Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia
por: Ma, Cheng-Cheng, et al.
Publicado: (2020)

Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia
por: Cho, Eun Kyung, et al.
Publicado: (2003)

Development and evaluation of LAMP, CPA and IMSA methods for rapid detection of the AML1/ETO fusion gene in acute myeloid leukemia
por: Yang, Zhigang, et al.
Publicado: (2018)

Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next-generation sequencing
por: Yu, Guopan, et al.
Publicado: (2019)

Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2017)

An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells
por: Zaidi, Sayyed K., et al.
Publicado: (2017)

ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
por: Golovine, Konstantin, et al.
Publicado: (2023)

Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2019)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation
por: Zhang, Yi-Fan, et al.
Publicado: (2022)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells
por: Barbetti, Valentina, et al.
Publicado: (2013)

Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia
por: Yu, Xianjun, et al.
Publicado: (2016)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

TAF1 plays a critical role in AML1-ETO driven leukemogenesis
por: Xu, Ye, et al.
Publicado: (2019)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kjp2fdscrf0vknrarusejo60an